Ruzasvir is under clinical development by Atea Pharmaceuticals and currently in Phase I for Hepatitis C. According to GlobalData, Phase I drugs for Hepatitis C have a 65% phase transition success rate (PTSR) indication benchmark for progressing into Phase II. GlobalData’s report assesses how Ruzasvir’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.

GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.

Ruzasvir overview

Ruzasvir is under development for the treatment of hepatitis C infection. The drug candidate is administered orally and targets NS5A antigen.

Atea Pharmaceuticals overview

Atea Pharmaceuticals (Atea) is a clinical stage biopharmaceutical company focused on discovering, developing and commercializing therapies to address the unmet medical needs of patients with life-threatening viral diseases including herpesvirus, hepatitis B, hepatitis C infections and HIV/AIDS. The company utilizes its purine nucleotide prodrug platform for the development of its products. Pipeline products of the company include AT527 for the treatment of COVID-19, AT-752 for dengue, AT-787 for Hepatitis C (HCV), AT-889 and AT-934 for the treatment of respiratory syncytial virus infection. Atea Pharmaceuticals is headquartered in Boston, Massachusetts, the US.

For a complete picture of Ruzasvir’s drug-specific PTSR and LoA scores, buy the report here.


GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.

GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in its clinical pathway (PTSR), as well as how likely the drug will be approved (LoA). This is based on a proprietary algorithm built from the drugs’ sales forecast, regulatory milestones, cost forecasts, WACC rate and other proprietary data sources found on GlobalData’s Pharmaceutical Intelligence Center.